KCNA3 and diabetes mellitus: Although there have been conflicting reports on the ability of the channel to improve insulin sensitivity based upon the pharmacological inhibition of peripheral Kv1.3 across different skeletal muscle cell lines (Straub et al., 2011; Hamilton et al., 2014) and exploration of the selectivity of Kv1.3 blockers themselves (Bartok et al., 2014), peripheral targeting of the Kv1.3 channel remains a strong therapeutic target for regulating diabetes, inflammation, and other diseases (Choi and Hahn, 2010; Pérez-Verdaguer et al., 2015).